Erlangen, Deutschland
Joined April 2010
- Tweets4.3K
- Following4.6K
- Followers717
- Likes10.2K
André Jefremow retweeted
Upadacitinib shows unique benefit early in TNF-naive perianal Crohn's disease. Our study covered 👇 healio.com/news/gastroentero…
André Jefremow retweeted
I’ve just updated the last 2 years of this IBD trial timeline
I think it may be useful to gain perspective: decades of trial names together reminds us how much the field has evolved and how fast it is still moving
Now including >250 trials🤩
Full quality ibd-eii.com/cheat-sheet/
André Jefremow retweeted
MUST READ📖
Joint @RomeFoundation & @IOIBD1 RAND/UCLA Recommendations for #Evaluation & #Managmt of #IBD with #IBS-like Symptoms @AGA_Gastro
pubmed.ncbi.nlm.nih.gov/4206…
📝Nomenclature: IBD with IBS-like symptoms
Evaluation🩺 🧫
Therapies
🥗Diet
💊Drugs💉
🧠Brain gut behavioral tx
André Jefremow retweeted
One-off application of CAR T-cell therapy leads to long term remission for a range of autoimmune diseases including SLE and more recently, IBD. Is this game changing therapy in the making? #UEGWeek
André Jefremow retweeted
CAR T-cell therapy was effective for a patient with multi-drug refractory ulcerative colitis.
nejm.org/doi/full/10.1056/NE…
André Jefremow retweeted
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
André Jefremow retweeted
The gastroenterology and immunology communities are buzzing after a landmark NEJM publication (Sept 25, 2025) reported the first successful use of autologous CD19 CAR T-cell therapy in ulcerative colitis (UC). The patient, who had exhausted biologics and immunosuppressants, achieved sustained remission with mucosal healing—off all medications—for more than eight months.
So, what exactly is CAR-T, and why is this so exciting for IBD? 👇
André Jefremow retweeted
Therapeutic B-cell targeting: the next big thing in #IBD treatment for selected pts? @RajaAtreya #MarkusNeurath
🌍✨ #Crohns #Colitis #MedTwitter
@IBD_FloMD @fgomollon @Y_ECCO_IBD @ibddoctor @IBDMD @DignassAxel @RestelliniS
nejm.org/doi/full/10.1056/NE…
André Jefremow retweeted
Cellular therapy is making big moves in so many spaces!! 🔥 🎯
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway. @NEJM
nejm.org/doi/full/10.1056/NE…
André Jefremow retweeted
Exciting times ahead 🥹
WOW @NEJM
CD19 CAR-T led to complete remission (clinical, biochemical, mucosal) in MDR UC
Patient failed on steroids, cyclosporine, 5-ASA, anti-TNF, JAKi, S1Ps, vedo, p19
By day 50 activity index 7↘️0 maintained 14 wks of FU
⬆️7kg
Mild adverse efect resolved spontaneously
link👇
André Jefremow retweeted
The 3-6-9 rule of normal intestinal diameters 🧠
🔸Small intestine: <3 cm
🔸Large intestine: <6 cm
🔸Caecum: <9 cm
André Jefremow retweeted
1/2
C. DIFFICILE AND LEUKOCYTOSIS
A not uncommon reason for inpatient hematology consultation: a patient (such as case shown in the graphic) with leukemoid reaction (WBC > 10^9/L) who has or turns out to have C. difficile infection (CDI).
André Jefremow retweeted
Here is my full review of the most impactful papers in IBD so far this year
SEQUENCE study compares Risankizumab (RIS) and Ustekinumab in people with Crohn's Disease who have lost response to an anti-TNT medication (IFX or ADA)
What is the significance of the picture?
André Jefremow retweeted
Original Article: Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease (SEQUENCE) nej.md/46dtnFY
Editorial: Interleukin-23 p19 and Interleukin-12 p40, Head-to-Head, against Gut Inflammation nej.md/4eZJVFc
ALT Diagram of interleukin-23 and interleukin-12 cytokines.
André Jefremow retweeted
🌟Ever found yourself doubting about IBD new drugs doses? or forgetting Thiopurine metabolism details?
I've been there too
So I thought it could help having "IBD Cheat Sheets" and that is what I did:
ibd-eii.com/ibdcheatsheet
I hope it helps as much as it helps me
1/2
#IBD
André Jefremow retweeted
Out now 🚨 in @AGA_Gastro is your latest update on selective IL-23p19 inhibition in IBD! Amongst other topics featuring discussion of pathogenesis, PD/PK, efficacy, safety, positioning, and more! Together with @JeanFredericCo1 @MehandruLab & @ryanungaro gastrojournal.org/article/S0…
André Jefremow retweeted
You've probably heard "don't give lactated ringers because it raises lactate"
This statement is ~98% false, but there's one crucial practice-changing fact that you need to know.
A 🧵 all about lactic acid and lactated ringers!
1/
André Jefremow retweeted
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
@Y_ECCO_IBD @IBD_FloMD @fgomollon
@RPanaccione @DignassAxel
jnj.com/media-center/press-r…
André Jefremow retweeted
Congratulations! Fantastic update 🤩
Relevant changes from 2019
✅do not stop biologicals prior surgery (2019 was conditional)
❌no fibrin glue for perianal
✅IFX & ADA for perianal
❓VEDO, UST, RIS, UPA in perianal
And much more relevant data!
Definitely 👍
Hot off the press : the #ECCO 2024 #Guidelines on Therapeutics in #CD: Medical Treatment. Excellently lead by Hannah Gordon and @IBD_MB, in close collaboration with ECCO GuiCom, @efcca and many clinicians globally. @Y_ECCO_IBD
academic.oup.com/ecco-jcc/ad…
André Jefremow retweeted
Hot off the press : the #ECCO 2024 #Guidelines on Therapeutics in #CD: Medical Treatment. Excellently lead by Hannah Gordon and @IBD_MB, in close collaboration with ECCO GuiCom, @efcca and many clinicians globally. @Y_ECCO_IBD
academic.oup.com/ecco-jcc/ad…